Description: Tonix Pharmaceuticals Holding Corp., a development stage specialty pharmaceutical company, focuses on the development of pharmaceutical products for the disorders of central nervous system. The company's lead product candidate includes TNX-102 SL, a dose and formulation of cyclobenzaprine for the treatment of fibromyalgia and post-traumatic stress disorder. It also has a pipeline of various other product candidates, including TNX-201, which is a treatment for certain types of headaches; and TNX-301. The company was founded in 2007 and is headquartered in New York, New York.
Home Page: www.tonixpharma.com
TNXP Technical Analysis
26 Main Street
Chatham,
NJ
07928
United States
Phone:
862 799 8599
Officers
| Name | Title |
|---|---|
| Dr. Seth Lederman M.D. | Co-Founder, Pres, CEO & Chairman |
| Mr. Bradley Saenger CPA, CPA | CFO & Treasurer |
| Dr. Gregory M. Sullivan M.D. | Chief Medical Officer & Sec. |
| Mrs. Jessica Edgar Morris | Chief Operating Officer |
| Dr. Herbert W. Harris M.D., Ph.D. | Exec. VP of Translational Medicine |
| Dr. Bruce L. Daugherty M.B.A., Ph.D. | Exec. VP of Research |
| Ms. Siobhan Fogarty B.Sc., M.Sc. | Exec. VP of Product Devel. |
| Dr. Darryl Rideout Ph.D. | Exec. VP of Experimental Chemistry |
| Dr. Sina Bavari Ph.D. | Exec. VP of Infectious Disease R&D |
| Dr. Daniel J. Clauw M.D. | Consultant |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.0865 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2012-05-10 |
| Fiscal Year End: | December |
| Full Time Employees: | 73 |